b'EARLY-STAGE CAPITAL & RETENTION GRANT RECIPIENTS EARLY-STAGE CAPITAL & RETENTION GRANT RECIPIENTSCetya was formed to develop therapies based on largazole for the treatment of cancer and hemoglobinopathies. Cetya has exclusive worldwide license to IPVitriVax We are partnering with prominent human and animal pharmaceutical companies globally to formulate their vaccines to be thermostable, and Cetya Therapeutics, Inc. created by Dr. Robert Williams at CSU. Cetya is focused on its most advanced program: the treatment of hemoglobin disorders such as sickle cell diseaserequire only a single injection(SCD). We have nominated a lead candidate which has been shown to outperform the market leader in SCD treatment both in vitro and in vivo with preliminary evidence of improved safety. Watchmaker Genomics specializes in the design, development and production of DNA- and RNA-modifying enzymes that enable high-growth applications Watchmaker Genomics in genomics, molecular diagnostics,and personalized medicine. Watchmaker is developing novel protein engineering and manufacturing platforms to cliexa is a modular digital intake and remote monitoring platform with clinical assessments, connected device data, payor claims data, andcreate best-in-class, proprietary reagents for the reading, writing, and editing of DNA. The company supplies these reagents to life science, diagnostic, and cliexa medication adherence. cliexa integration services and rules engine fully supports bi-directional EMR integration, enabling custom clinicianclinical sequencing companies.alerts, patient notifications, and reminders to engage patients with their treatment plans while providing clinical and compliance metrics for documentation and quality reporting. Xtract Medical has built and patented a disruptive technology in stroke treatment that significantly improves patient outcomes, fits with existing Xtract Medical catheters, and simplifies the surgeons life.Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action small molecule drugs for Crestone, Inc. serious bacterial infections including Clostridioides difficile infection (CDI), resistant Gram-positive infections such as methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE), and chronic infections such as NTM disease.PROOF-OF-CONCEPT GRANT RECIPIENTSEmergy, Inc. Emergy has developed a new form of edible protein that has three times the protein content of beef, at 60% the price of chicken, and produces 2000 times the protein per acre than soy or pea. UNIVERSITY TECHNOLOGY TRANSFER OFFICE PRINCIPAL INVESTIGATOR PROJECT TITLEExum is developing a new scientific instrument which is capable of measuring, mapping and quantifying any element or organic compound.Colorado School of MinesFred Sarazin, Ph.D. Treatment of nonmelanoma skin cancer using radioactive film therapy (RAFT)Further, we are making it the easiest-to-use instrument on the market, with no Ph.D. required. We are building this tool to replace the dated, time- Office of Technology TransferExum Instruments, Inc.consuming, and frustrating instruments and workflows of current instruments. We accomplish this by combining new analytical technologies with Colorado School of MinesTerry Lowe, Ph.D. Cost-effective manufacturing for an impact absorbing hybrid material systemmodern software design sensibilities. Office of Technology TransferImpressio is the first and only company to develop and market a safe helmet liner using a patented energy absorbing material and stateofthe Colorado State University Ventures, Inc. Kathryn Wotman, D.V.M. Development of a novel topical ocular immunotherapy for the treatment of viral art additive manufacturing to 3Dprint player/userspecific helmet liners to reduce concussion and protect the head. This new approach has thediseases of the eyeImpressio, Inc. potential to be used for any helmet technology to improve safety (such as football, military, and bike helmets). There is a growing trend among consumers and professionals to use 3D Printing and new materials. Colorado State University Ventures, Inc. Christian Puttlitz, Ph.D. Direct electromagnetic coupling for diagnostic prediction of fracture healingColorado State University Ventures, Inc. Garret Miyake, Ph.D. Dihydroacridine organic photocatalysts for light-driven synthesis of medicinally Momentum Optics is leveraging semiconductor processing techniques to develop an innovative manufacturing technology capable of producing opticalimportant small moleculesMomentum Optics components about 10X less expensively and 5-10X faster than traditional methods. We solve the problem of long lead-times for custom optical lenses, aColorado State University Ventures, Inc. Thomas Hansen, Ph.D. Molecular marker for embryo quality and embryo transfer successpain point for many companies as they seek a firsttomarket advantage in an effort to capture early market share and create brand awareness.National Jewish HealthMichael Strong, Ph.D. Rapid whole genome sequencing diagnostic for nontuberculous mycobacterial Stroke and cardiac arrest affect millions of patients each year. Reestablishment of blood flow to the brainalthough lifesavingdoes not address theTechnology Transfer Office infectionsNeurexis Therapeutics, Inc. substantial impact on quality of life and healthcare costs associated with the resulting neuronal death and cognitive impairment. No drugs are available,National Jewish HealthAnthony Gerber, M.D., Ph.D. Small molecule discovery to augment expression of the antiinflammatory ubiquitin leaving a tremendous market opportunity for a product that significantly reduces damage to the brain. Neurexis is directly addressing this unmet need. Technology Transfer Office editor, A20.National Jewish HealthSanny Chan, M.D., Ph.D. Quantifying exposure levels to dog specific allergensQuorum brings state-of-the-art technology and personalized service to anyone in need of prosthetic or orthotic devices to improve their mobility.Technology Transfer OfficeQuorum Orthopedics, Inc. With a wide range products tailored to individual needs and an all-inclusive clinic, Quorum provides patients with the maximum and highest quality mobility possible. National Jewish HealthTasha Fingerlin, Ph.D. Enabling comprehensive diagnosis of sub-acute infection in chronic respiratory disease Technology Transfer Office via high sensitivity next generation sequencing.SafeSpout is the most accurate lead test for in-home drinking water, accurately detecting total lead concentrations well below 1 part-per-billion.University of Colorado Boulder Christopher Lowry, Ph.D. Lead compound discovery from environmental mycobacteria strains for treatment of PTSDSafeSpout Spout is a subscriptionbased, IOT device that utilizes singleuse test cartridges. It establishes consumer confidence in the water that they drink;Developing an inexpensive at-home test (SickStick) that will indicate whether someone democratizes aggregated community data; connects consumers with mitigation solutions; accelerates lead service line replacement initiatives;University of Colorado Boulder Sara Sawyer, Ph.D. has been infected with a virus or bacteria.and supports corporate sustainability programs.University of Colorado Boulder Rafael Piestun, Ph.D. Ultra-thin endoscopeScientists and doctors can cure diseases in a test tube using nucleic acid drugs, however delivery to the patient remains a challenge andUniversity of Colorado Boulder Roy Parker, Ph.D. PARN as a target for treament of specific categories of human cancersSiVEC Biotechnologies biopharma is looking for a delivery solution that works. SiVEC is offering a delivery system for nucleic acid therapeutics which provides a largeUniversity of Colorado Boulder Xuedong Liu, Ph.D. Programmable gectosomes for delivery of therapeutic nucleic acids and proteinstherapeutic window, longterm payload stability, and tissue targeted delivery with a favorable safety profile. Potential targets are broad and include influenza, cancer, genetic disorders, and diabetes. University of Colorado Boulder Min Han, Ph.D. Transformative treatment of anemia: using enterobactin to relieve adverse side effects caused by iron supplementationSkyland Analytics develops cloud-based data management software for drug manufacturers. Drug companies are universally reliant on paperUniversity of Colorado Denver Maria Valeria Canto-Soler, Ph.D. Advanced biomaterial systems for stem cell-derived retinal transplantsSkyland Analytics, Inc. records and spreadsheets for the management of critical data and on 3rd parties for drug development and production. The Skyland PIMS dataUniversity of Colorado Denver Cem Altunbas, Ph.D. An ultracompact CT scanner for point-of-care imagingcollaboration platform enables customers to cohere paper, spreadsheet and digital data throughout the supply chain while meeting FDA guidelines for data integrity, and data visibility between drug owner and their manufacturers. University of Colorado Denver Jay Hesselberth, Ph.D. Methods to measure functional heterogeneity among single cellsUniversity of Colorado Denver Tom Flaig, M.D. Multifunctional nanoclusters for detection and treatment of bladder cancerWe are a large, highly automated, cGMP manufacturer that happens to make compounded medications in prefilled syringes for hospital procedures. WeUniversity of Colorado Denver Devatha Nair, Ph.D. Oral Biofilm disruption and selective inhibition of s.mutans biofilmsSTAQ Pharma, Inc. focus on the Pediatric Hospitals and their needs, but also adult hospitals where the medication use is relevant to both. We emphasize Safety, Transparency, Availability, and Quality in everything we do. We are the first in our industry to develop and deploy robotic syringe filling in compounded medications. University of Colorado Denver Kimberley Bruce, Ph.D. LPL activators as novel therapeutics for ADUniversity of Colorado Denver Maria Nagel, M.D. Repurposing neurokinin-1 receptor antagonists to treat varicella zoster virus infectionTransverse Medical Inc. has developed the POINT-GUARD device to address the costly clinical unmet need for complete stroke protection for the patientsUniversity of Colorado Denver Zhirui Wang, D.V.M., Ph.D. IL2CCR4 bispecific immunotoxin targeting cutaneous tcell lymphomaTransverse Medical, Inc. brain during Transcatheter Aortic Valve Replacement procedures, a $12.5B annual market. Utilizing novel technology to create dynamic double edge sealing, the POINT-GUARD adapts and conforms to complex arch anatomy, making it the only true solution for Complete Cerebral Embolic Protection. University of Colorado Denver Kristine Kuhn, M.D., Ph.D. Novel inhibitors of trimethylamine lyase for the treatment of rheumatoid arthritisUniversity of Colorado Denver Cristos Ifantides, M.D., M.B.A. iSense: A firstinclass therapy for insufficient pupil dilation18BIOSCIENCECOLORADO//2020-2021 BIOSCIENCECOLORADO//2020-202119'